All In Biotech

Drug Trial Radar · NCT03315130

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Jul 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

45

Actual

Start

Oct 11, 2017

Primary completion

Dec 10, 2018

Study completion Nov 19, 2020

Sponsor

Lead sponsor
Ra PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 19, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • zilucoplan (RA101495)Drug

    Daily subcutaneous (SC) injection

  • PlaceboDrug

    Daily subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) ScoreTime frame: From Baseline to Week 12

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • Diagnostic and Medical Clinic - Mobile

    Mobile, Alabama

  • The Research Center of Southern California

    Carlsbad, California

  • UCLA Medical Center

    Los Angeles, California

  • University of California Irvine Health ALS and Neuromuscular Center

    Orange, California

  • Yale University

    New Haven, Connecticut

  • George Washington University

    Washington D.C., District of Columbia

  • University of Florida

    Jacksonville, Florida

  • University of South Florida

    Tampa, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • University of Maryland

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts

  • Wayne State University

    Detroit, Michigan

  • Michigan State University

    East Lansing, Michigan

  • University of Buffalo

    Buffalo, New York

  • Hospital for Special Surgery

    New York, New York

  • Mount Sinai Hospital

    New York, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Ohio State University

    Columbus, Ohio

  • Allegheny Neurological Associates

    Pittsburgh, Pennsylvania

  • Wesley Neurology Clinic

    Cordova, Tennessee

  • University of Texas Southwestern

    Dallas, Texas

  • University of Utah

    Salt Lake City, Utah

  • University of Vermont

    Burlington, Vermont

  • Center for Neurological Disorders

    Milwaukee, Wisconsin

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • London Health Sciences Centre University Hospital

    London, Ontario, Canada

  • Toronto General Hospital

    Toronto, Ontario, Canada

  • Montreal Neurological Institute and Hospital

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.